Seres Therapeutics (MCRB) officer sells shares after RSU vesting under 10b5-1 plan
Rhea-AI Filing Summary
Seres Therapeutics, Inc. officer Matthew R. Henn reported several equity transactions. On May 15, 2026, he exercised restricted stock units (RSUs) that converted into 238 shares of common stock at a conversion price of $0.00 per share. The RSUs each represent a contingent right to one share of common stock and vest in quarterly installments. On May 18, 2026, he completed an open-market sale of 77 common shares at $7.53 per share, executed under a pre-arranged Rule 10b5-1 instruction adopted to cover taxes related to RSU vesting. Following these transactions, he directly held 7,838 common shares and 422 RSUs as reported in the filing, indicating a relatively small sale compared with his remaining equity position.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
4 txns
Insider
Henn Matthew R
Role
See Remarks
Sold
77 shs ($579.81)
Approx. gross sale proceeds
$579.81
Approx. exercise cost
$0.00
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 77 | $7.53 | $579.81 |
| Exercise | Restricted Stock Units | 141 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units | 97 | $0.00 | $0.00 |
| Exercise | Common Stock | 238 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Stock Units — 1,105 shares (Direct);
Common Stock — 7,838 shares (Direct)
Footnotes (4)
- F1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- F2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on April 13, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
- F3. The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
- F4. The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
Key Figures
Shares sold: 77 shares
Sale price: $7.53 per share
Common shares after sale: 7,838 shares
+5 more
8 metrics
Shares sold
77 shares
Open-market sale of common stock on May 18, 2026 at $7.53
Sale price
$7.53 per share
Price for 77 common shares sold on May 18, 2026
Common shares after sale
7,838 shares
Direct holdings of common stock following reported transactions
Shares from RSU conversion
238 shares
Common shares acquired via RSU exercises on May 15, 2026
RSUs converted (lot 1)
97 RSUs
Restricted stock units converting into common stock on May 15, 2026
RSUs converted (lot 2)
141 RSUs
Additional restricted stock units converting into common stock on May 15, 2026
RSUs remaining
422 RSUs
Restricted stock units reported as held after RSU transactions
Rule 10b5-1 adoption date
April 13, 2023
Date of instruction governing tax-related share sales
Key Terms
Restricted Stock Units, Rule 10b5-1, open market, derivative security, +1 more
5 terms
Restricted Stock Units financial
"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Rule 10b5-1 regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on April 13, 2023."
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
open market financial
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on April 13, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."
An open market is a system where buying and selling of goods, services, or financial assets happen freely without restrictions or special controls. For investors, it means they can trade assets easily and quickly, which helps determine fair prices based on supply and demand. This environment encourages transparency and competition, making it easier to buy or sell with confidence.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
contingent right financial
"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did Matthew R. Henn report at Seres Therapeutics (MCRB)?
Matthew R. Henn reported exercising restricted stock units into 238 Seres Therapeutics shares and selling 77 common shares. The sale occurred at $7.53 per share, alongside RSU vesting and settlement into common stock under his compensation arrangements.
What restricted stock unit activity did Matthew R. Henn report for Seres Therapeutics (MCRB)?
He reported the conversion of 97 and 141 restricted stock units into an equal number of Seres Therapeutics common shares. These RSUs vest in quarterly installments after initial 25% vesting dates in February 2024 and February 2025, with no stated expiration date.